Recent advances in the pharmacotherapy of major depression

Archives of Psychiatric Nursing

Volumn 10, Issue 6, 1996, Pages 355-364

  Glod, Carol A ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450;

DEPRESSION; DOSE RESPONSE; DRUG EFFECT; METHODOLOGY; PSYCHIATRIC NURSING; REVIEW;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; PSYCHIATRIC NURSING;

EID: 0030345872     PISSN: 08839417     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0883-9417(96)80049-5     Document Type: Article

References (12)

1. Baron, B.M., Ogden, A.-M., Siegel, B.W., Stegeman, J., Ursillo, R.C., & Dudley, M.W. (1988). Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine. European Journal of Pharmacology, 154, 125-134.
2. Benet, L.Z., Kroetz, O.L., & Sheiner, L.B. (1996). Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Oilman (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed (pp. 3-27). New York, NY: McGraw-Hill.
3. Blier, P., de Montigny, C., & Chaput, Y. (1990). A role of serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Journal of Clinical Psychiatry, 51(Suppl. 4), 14-20.
4. Clerc, G.E., Ruimy, P., Verdeau-Paillès, J., on behalf of the Venlafaxine French Inpatient Study Group (1994). A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology, 9, 139-43.
5. Coppen, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113, 1237-1264.
6. De Vane, C.L. (1994a). Pharmacokinetics of the newer antidepressants: clinical relevance. American Journal of Medicine, 97(Suppl. 6A), 135-235.
7. DeVane, C.L. (1994b). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55 (Suppl. 12), 38-45.
8. Ereshefsky, L., Overman, G.P., & Karp, J.K. (1995). Current psychotropic dosing and monitoring guidelines. Primary Psychiatry, 2(5), 42-53.
9. Feighner, J.P. (1995). Cardiovascular safety in depressed patients: focus on venlafaxine. Journal of Clinical Psychiatry, 56, 574-579.
10. Golden, R.N., Bebchuk, J.M., & Leatherman, M.E. (1995). Trazodone and other antidepressants. In A.F. Schatzberg & C.B. Nemeroff (Eds.). Textbook of Psychopharmacology (pp. 195-213). Washington, DC: American Psychiatric Press.
11. Greenblatt, D.J. (1995). Principles of pharmacokinetics and pharmacodynamics. In Schatzberg, A.F. & Nemeroff, C.B. (Eds.). Textbook of Psychopharmacology (pp. 125136). Washington, DC: American Psychiatric Press.
12. Hays, R.D., Wells, K.B., Sherbourne, C.D., Rogers, W., & Spritzer, K. (1995). Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Archives of General Psychiatry, 52, 11-19.